{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:02Z","timestamp":1787002982632,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Palbociclib in combination with endocrine therapy increases progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer (BC). In this study, we retrospectively evaluated safety in the first patient treated with concurrent use of palbociclib and radiation therapy (RT) in the Curie Institute. Between April 2017 and August 2019, 30 women with metastatic BC received locoregional and\/or symptomatic irradiation at a metastatic site concurrently with palbociclib. The most common acute toxicities were radiodermatitis and neutropenia. Palbociclib had to be discontinued during RT in three locally treated patients who developed grade 3 radiodermatitis and febrile neutropenia, grade 2 dysphagia and metastatic disease progression, respectively. After a follow-up of at least 6 months, none of the patients had late toxicity. Concomitant administration of palbociclib with RT was reasonably well tolerated in our series of 30 patients. More prospective data with longer follow-up are needed to confirm these results.<\/jats:p>","DOI":"10.1038\/s41416-020-0957-9","type":"journal-article","created":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T19:02:58Z","timestamp":1593370978000},"page":"905-908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5512-4161","authenticated-orcid":false,"given":"Arnaud","family":"Beddok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Ars\u00e8ne","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cottu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlia","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"957_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"N. Engl. J. Med."},{"key":"957_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"957_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.radonc.2017.09.010","volume":"126","author":"S Hans","year":"2018","unstructured":"Hans, S., Cottu, P. & Kirova, Y. M. Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients. Radiother. Oncol. 126, 181 (2018).","journal-title":"Radiother. Oncol."},{"key":"957_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.08.096","volume":"42","author":"I Meattini","year":"2018","unstructured":"Meattini, I., Desideri, I., Scotti, V., Simontacchi, G. & Livi, L. Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer. Breast Edinb. Scotl. 42, 1\u20132 (2018).","journal-title":"Breast Edinb. Scotl."},{"key":"957_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.adro.2019.03.011","volume":"4","author":"M Chowdhary","year":"2019","unstructured":"Chowdhary, M., Sen, N., Chowdhary, A., Usha, L., Cobleigh, M. A., Wang, D. et al. Safety and efficacy of palbociclib and radiation therapy in patients with metastatic breast cancer: initial results of a novel combination. Adv. Radiat. Oncol. 4, 453\u2013457 (2019).","journal-title":"Adv. Radiat. Oncol."},{"key":"957_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11060-019-03260-6","volume":"144","author":"NB Figura","year":"2019","unstructured":"Figura, N. B., Potluri, T. K., Mohammadi, H., Oliver, D. E., Arrington, J. A., Robinson, T. J. et al. CDK 4\/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J. Neurooncol. 144, 583\u2013589 (2019).","journal-title":"J. Neurooncol."},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","volume":"46","author":"E Ippolito","year":"2019","unstructured":"Ippolito, E., Greco, C., Silipigni, S., Dell\u2019Aquila, E., Petrianni, G. M., Tonini, G. et al. Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity. Breast 46, 70\u201374 (2019).","journal-title":"Breast"},{"key":"957_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2018.09.020","volume":"131","author":"T Kawamoto","year":"2019","unstructured":"Kawamoto, T., Shikama, N. & Sasai, K. Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment. Radiother. Oncol. 131, 240\u2013241 (2019).","journal-title":"Radiother. Oncol."},{"key":"957_CR9","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.ijrobp.2018.07.1673","volume":"102","author":"R Kalash","year":"2018","unstructured":"Kalash, R., Iarrobino, N. A., Beriwal, S., Sun, M., Glaser, S. M. & Champ, C. E. Palbociclib enhances pulmonary fibrosis in patients undergoing thoracic radiation therapy: a case series and review of the literature. Int. J. Radiat. Oncol. 102, e610 (2018).","journal-title":"Int. J. Radiat. Oncol."},{"key":"957_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.rpor.2019.03.001","volume":"24","author":"JA Messer","year":"2019","unstructured":"Messer, J. A., Ekinci, E., Patel, T. A. & Teh, B. S. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: a case report. Rep. Pract. Oncol. Radiother. 24, 276\u2013280 (2019).","journal-title":"Rep. Pract. Oncol. Radiother."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0957-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:09:06Z","timestamp":1684602546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0957-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,9,15]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0957-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"29 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received ethical approval after being submitted to the Institut Curie\u2019s breast cancer ethics committee. The study was presented and approved by the Institut Curie Breast Cancer Research and Treatment Group. Our project does not include any interaction or intervention with human subjects, or include any access to identifiable private information; then, the project does not require IRB review, and the ethics board has waived the requirement for subjects to provide informed consent to participate. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no funding.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}